# US 2020/0400693 A1 · Methods for the detection of autologous blood-doping

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0400693 A1
- Document ID: US20200400693A1
- Status: Published application
- Kind: A1
- Application number: 16/976,936
- Filed: 2019-03-01
- Published: 2020-12-24
- Earliest claimed: 2018-03-01
- Applicants: Pro Test Diagnostics AB
- Inventors: Christer MALM; Nelson KHOO; Irene GRANLUND; Pernilla LINDÉN; Michael HALL; Raik WAGNER
- Web page: https://patentgrep.com/patent/US20200400693A1

## CPC

- G01N 33/80: involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)}
- C07K 4/00: Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- C07K 7/00: Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C12Y 304/21004: Trypsin (3.4.21.4)
- G01N 2560/00: Chemical aspects of mass spectrometric analysis of biological material
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to the identification of peptides, and the corresponding proteins, that can be used in methods for the detection of autologous blood doping. More specifically, the invention relates to methods comprising tryptic digestion of samples of isolated red blood cell (RBC), specifically isolated RBC cytosol, followed by peptide mapping using liquid chromatography tandem-mass spectroscopy (LC-MS/MS). The methods according to the invention which enable detection of increased levels of certain peptides in samples from subjects that have been subjected to autologous blood doping, compared to samples from non-doped control subjects.

## Claims

### Claim 1

A method for detection of autologous blood-doping with cryopreserved blood in a subject, said method comprising the step:
i) identifying whether said subject has or has not been autologous blood doped based on differences in level of one or more specific peptides between an isolated red blood cell cytosol sample prepared from a blood sample from said subject compared to the level of the same specific peptides from an isolated red blood cell cytosol sample prepared from a reference blood sample, such levels having been determined by generation of a proteolytic peptide map for each of the blood sample and the reference blood sample.

### Claim 2 (depends on 1)

A method as claimed in claim 1 further comprising performing before step (i) one or more of the steps of:
x) determining the level of one or more specific peptide in the isolated red blood cell cytosol sample prepared from the blood sample obtained from said subject;
y) determining the level of one or more specific peptide in an isolated red blood cell cytosol sample prepared from a reference blood sample;
z) determining any difference in level of said one or more specific peptides compared to the level of the same specific peptides in a reference blood sample.

### Claim 3 (depends on 1, 2)

A method as claimed in either of claim 1 or 2, said method comprising the steps:
a) generating a proteolytic peptide map of an isolated red blood cell cytosol sample prepared from a blood sample obtained from said subject;
b) determining the levels of one or more specific peptide identified in the peptide map obtained in step a)
c) determining the difference in level of said one or more specific peptides compared to the level of the same specific peptides in reference peptide maps obtained from an isolated red blood cell cytosol sample prepared from a reference blood sample; and
d) identifying whether said subject has or has not been autologous blood doped with cryopreserved blood based on differences in the level of said specific peptides compared to the level of the same specific peptides in said reference peptide maps.

### Claim 4

A method as claimed in any previous claim wherein the reference blood sample is from a non-doped subject.

### Claim 5

The method according to any previous claim wherein said one or more specific peptides is or are one or more peptides derived from one or more of the proteins listed in Table 3.

### Claim 6

The method according to any previous claim wherein said one or more specific peptides is or are one or more peptides selected from the list of peptides comprising SEQ ID Nos: 1-78.

### Claim 7

The method according to any previous claim wherein said one or more specific peptides is or are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, or 78 peptides selected from the list of peptides comprising SEQ ID Nos: 1-78.

### Claim 8

The method according to any previous claim wherein said one or more specific peptides is or are one or more peptides derived from one or more of the proteins selected from: Threonine-tRNA ligase, cytoplasmic; 26S proteasome non-ATPase regulatory subunit 4; Isoform 2 of T-complex protein 1 subunit theta; Tubulin beta-4B chain UV excision repair protein RAD23 homolog B; 26S proteasome non-ATPase regulatory subunit 13; Isoform 2 of Ubiquitin-like modifier-activating enzyme 1; Isoform 3 of Calpastatin; Uroporphyrinogen-III synthase; and Casein kinase II subunit alpha.

### Claim 9

The method according to any previous claim wherein said one or more specific peptides is or are one or more peptides consisting of the amino acid sequence of one of the peptides SEQ ID Nos: 1, 7, 8, 9, 10, 12, 14, 22, 24, 34, and 78.

### Claim 10

The method according to any previous claims wherein the step of generating the proteolytic peptide map comprises protease digestion that is performed using one or more of the proteases selected from trypsin, chymotrypsin, Lys-C, Gly-C, Asp-N, Arg-C, papain.

### Claim 11 (depends on 10)

The method according to claim 10 wherein the protease digestion is performed by trypsin digestion.

### Claim 12

The method according to any previous claim wherein the peptide mapping is performed by the combination of liquid chromatography (LC) with mass spectrometry (MS), and preferably wherein the MS is tandem mass spectrometry (MS/MS).

### Claim 13

Use of a peptide selected from the list of peptides comprising the peptides SEQ ID Nos: 1-78 in a method as described in any one of the preceding claims for detection of autologous blood-doping with cryopreserved blood.

### Claim 14

A peptide consisting of the amino acid sequence of one the peptides SEQ ID Nos:1, 7, 8, 14, and 34.

### Claim 15 (depends on 14)

A kit comprising one or more of the peptides according to claim 14.

### Claim 16

A method for the identification of biomarkers for the detection of autologous blood-doping with cryopreserved blood, said method comprising the steps;
i) identifying differences in the level of one or more peptides between an isolated red blood cell cytosol sample prepared from blood samples obtained from one or more subjects having received an infusion of autologous blood and an isolated red blood cell cytosol sample prepared from blood samples obtained from one or more control subjects not having received an infusion of autologous blood, such levels having been identified following generation a proteolytic peptide map of the blood samples; and
ii) identifying peptides being present in significant different levels, as a biomarker for autologous blood doping with cryopreserved blood.

### Claim 17 (depends on 16)

A method as claimed in claim 16, said method comprising the steps;
i) generating proteolytic peptide maps of an isolated red blood cell cytosol sample prepared from blood samples obtained from one or more individuals having received an infusion of autologous blood,
ii) generating proteolytic peptide maps of an isolated red blood cell cytosol sample prepared from blood samples obtained from one or more control individuals not having received an infusion of autologous blood,
iii) identifying differences in the level of one or more peptides in the peptide maps obtained in step i) compared to peptide maps obtained in step ii), and
iv) identifying peptides being present in significant different levels, and the corresponding proteins, as a biomarker for autologous blood doping with cryopreserved blood.

### Claim 18 (depends on 16, 17)

The method according to claim 16 or 17, wherein said cytosol is depleted of hemoglobin or has a reduced level of hemoglobin.
